Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Rudolf Weigl Street, 53-114 Wroclaw, Poland.
J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):399-402. doi: 10.1016/j.jsbmb.2010.03.017. Epub 2010 Mar 12.
Geometric isomers (5E,7E) of major active metabolites of vitamin D3 [1alpha,25(OH)2D3 and (24R)-1,24(OH)2D3] were synthesized by a new convenient procedure. Vitamin D triene system of the metabolites was first derivatized as a Diels-Alder adduct. Removal of the triene protecting group, in a key synthetic step, yielded the title compounds PRI-2208 and PRI-2209, respectively. The analogs were examined for their antiproliferative activity in vitro against human breast cancer cells (MCF-7) and promyelocytic leukemia (HL-60) cells. The activity was compared with one of the parent compounds. Both analogs examined revealed similar or higher antiproliferative activity compared to 1alpha,25(OH)2D3 or to (24R)-1,24(OH)2D3. The studies of calcemic activity in vivo showed that analogs PRI-2208 and PRI-2209 did not influence the serum calcium level in doses, in which 1alpha,25(OH)2D3 or (24R)-1,24(OH)2D3 significantly increased this level. The antitumor activity of these analogs in the LLC mice tumor model was studied. Analog PRI-2208 was found to be more active in inhibiting LLC tumor growth than 1alpha,25(OH)2D3, as well as than PRI-2191 and PRI-2209.
维生素 D3[1α,25(OH)2D3 和 (24R)-1,24(OH)2D3]的主要活性代谢物的几何异构体(5E,7E)通过一种新的方便的方法合成。代谢物的维生素 D 三烯系统首先被衍生化为 Diels-Alder 加合物。在关键的合成步骤中,三烯保护基团的去除分别得到标题化合物 PRI-2208 和 PRI-2209。对这些类似物进行了体外人乳腺癌细胞(MCF-7)和早幼粒细胞白血病(HL-60)细胞的增殖抑制活性检测。将活性与一种母体化合物进行了比较。与 1α,25(OH)2D3 或 (24R)-1,24(OH)2D3 相比,所研究的两种类似物均显示出相似或更高的增殖抑制活性。体内钙活性研究表明,在 1α,25(OH)2D3 或 (24R)-1,24(OH)2D3 显著增加血清钙水平的剂量下,类似物 PRI-2208 和 PRI-2209 均未影响血清钙水平。在 LLC 小鼠肿瘤模型中研究了这些类似物的抗肿瘤活性。发现类似物 PRI-2208 抑制 LLC 肿瘤生长的活性比 1α,25(OH)2D3 更强,比 PRI-2191 和 PRI-2209 更强。